Farber lipogranulomatosis
Farber Lipogranulomatosis (also known as Farber's disease, Farber's lipogranulomatosis, or ceramidase deficiency) is a rare, inherited metabolic disorder that belongs to a group of diseases known as lysosomal storage diseases. The disease is named after Dr. Sidney Farber, the pathologist who first described the condition in 1952.
Etiology[edit | edit source]
Farber lipogranulomatosis is caused by mutations in the ASAH1 gene, which provides instructions for producing an enzyme called acid ceramidase. This enzyme is responsible for breaking down a type of fat called ceramide. Mutations in the ASAH1 gene disrupt the normal function of acid ceramidase, leading to an accumulation of ceramide within cells. This buildup of ceramide is toxic and leads to the signs and symptoms of Farber lipogranulomatosis.
Symptoms[edit | edit source]
The symptoms of Farber lipogranulomatosis typically appear in early infancy and may include a hoarse voice or weak cry, small lumps of fat under the skin and in other tissues (lipogranulomas), and swollen and painful joints. Over time, individuals with Farber lipogranulomatosis may develop neurological problems such as developmental delay and progressive weakness.
Diagnosis[edit | edit source]
Diagnosis of Farber lipogranulomatosis is based on the clinical symptoms, and can be confirmed by genetic testing to identify mutations in the ASAH1 gene. Additionally, a biopsy of affected tissues can reveal the characteristic lipogranulomas.
Treatment[edit | edit source]
There is currently no cure for Farber lipogranulomatosis. Treatment is supportive and aims to manage the symptoms. This may include pain management, physical therapy for joint contractures, and respiratory support for individuals with lung involvement.
Prognosis[edit | edit source]
The prognosis for individuals with Farber lipogranulomatosis varies depending on the severity of symptoms. Some individuals with a severe form of the disease do not survive past early childhood, while those with milder forms may live into adolescence or adulthood.
See also[edit | edit source]
This rare disease-related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD